Skip to main content

Founded in 2020, Genflow conducts its R&D in Belgium at the BioPark, Gosselies. Genflow is one of the few European listed companies focused on longevity biotech discovery to increase human life spans with better health. It was listed on the London Stock Exchange (GENF) in January 2022.  In 2023, Genflow is also traded in the USA on OTC.QB (GENFF).  Genflow’s gene therapies are based on a proprietary  and patented variant of the SIRT6 gene only found in centenarians.  These gene therapies are designed to retard the aging process and to reduce the incidence of age-related diseases and are developed for the treatment of NASH (a liver disease with no therapy), Werner Syndrome (a disease of accelerated aging) and sarcopenia (a disease of muscle loss). Genflow owns and is developing proprietary technology for new therapeutic approaches and treatments with patents pending on unique drug treatments and delivery systems.

Genflow currently develops 3 pre-clinical programs:

  1. NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by inflammation and liver cell damage leading to fibrosis and cirrhosis. The prevalence of NASH is increasing globally. It is becoming the main cause of liver transplant and hepatocellular carcinoma. Currently, there are no approved pharmacological treatments for NASH. This creates a significant unmet medical need and an opportunity for innovative therapies. A centSIRT6 based-gene therapies represent an exciting and novel avenue for intervention.  CentSIRT6 plays a role in various cellular processes, including metabolism, inflammation and fibrosis and could hold promise as a targeted effective treatment.. Successful treatments for NASH could have a significant impact on patient outcomes and represent a valuable asset in the pharmaceutical market.
  1. Werner syndrome is a rare genetic disorder characterized by accelerated aging. Individuals with Werner syndrome typically exhibit symptoms of premature aging, including skin changes, cataracts, and an increased risk of age-related diseases such as cancer and cardiovascular problems. There are no specific and approved treatments for Werner syndrome. The lack of targeted therapies for this rare genetic disorder creates an opportunity for innovative approaches to address the underlying genetic and molecular mechanisms.
  2. The sarcopenia program is conducted in collaboration with Revatis. Sarcopenia is a medical condition characterized by the loss of muscle mass, strength, and function that occurs with aging. As the global population ages, sarcopenia becomes a significant public health concern. Mitochondria play a crucial role in the development of sarcopenia. As individuals age, there is a decline in mitochondrial function, leading to impaired energy production and muscle function. Targeting mitochondria for therapeutic interventions is a logical approach to address the underlying mechanisms of sarcopenia. The aging population and the increasing awareness of age-related conditions, including sarcopenia, create a significant market opportunity for innovative therapies. Companies working on novel treatments for age-related conditions may benefit from the growing demand for solutions that improve the quality of life in the elderly population.


Dr Eric Leire, CEO
+32 477 49 58 81


Genflow Biosciences corporate presentation